.Attributes Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin resulted in enhanced progression-free and also total survival, causing FDA approval and also a new treatment possibility for patients.